Top Blood Cancer News from 2022

Article

From updates on clinical trials to a podcast where an oncology nurse shares how her son’s leukemia diagnosis changed her life, here are CURE®’s top blood cancer articles from the year 2022.

The blood cancer space has changed in 2022, and ongoing clinical trials will continue to shape the field in the future.

CURE® gathered our top blood cancer news and stories from 2022. Here’s what we found:

Here are the top 5 blood cancer articles from 2022 that were published on curetoday.com.

Here are the top 5 blood cancer articles from 2022 that were published on curetoday.com.

FDA Lifts Partial Hold on Blood Cancer Trial, Patient Enrollment Allowed to Continue

The TakeAim Leukeia and TakeAim Lymphoma clinical trials were put on hold in April, after the Food and Drug Administration (FDA) had questions about the safety of emavusertib, the drug being studied. Then, when the drug’s developer provided more information about rhabdomyolysis, a potentially fatal condition where damaged muscle breaks down, causing muscle cell contents to enter the bloodstream to the FDA, the agency allowed the trials to continue.

First Patient Receives Investigational CAR-T Cell Therapy in Trial Assessing the Treatment for Lymphoma, Leukemia

This October, a clinical trial kicked off investigating MB-106, an investigational CAR-T cell therapy for patients with relapsed/refractory lymphoma and leukemia subtypes. CAR-T cell therapy is a treatment type where a patient’s immune system is engineered to find and fight cancer cells and has become increasingly popular in the treatment of hematologic malignancies.

Mortality Risk Later in Life May Be Increased in Childhood Leukemia Survivors With Down Syndrome

According to research published in Cancer, adults with Down syndrome who survived childhood leukemia had an increased chance of dying five years after diagnosis compared to both childhood leukemia survivors who did not have Down syndrome and people with Down syndrome who do not have a history of leukemia.


Triple-Class Refractory Myeloma Requires ‘Greater Attention to Symptoms'

When patients have a diagnosis of multiple myeloma that does not respond to three different treatment types (known as “triple-refractory disease”) they may face decreased quality of life. However, an expert from the Wake Forest School of Medicine in Winston-Salem, North Carolina explained that there are resources to treat pain and other symptoms in this patient population.

Uncharted Territory: How a Cancer Nurse Navigated Her Child’s Leukemia Diagnosis

In this episode of the “Cancer Horizons” podcast , oncology nurse Janice Post-White explains how her life was changed when her son was diagnosed with blood cancer. Post-White’s experience led to her writing a book about her experiences called, “Standing at Water’s Edge.”
“I went into nursing because I wanted to feel connected, and I wanted to make a difference,” Post-White stated. “I learn from other people's strengths. And if they can do it, you can do it.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Mikhael in an interview with CURE
Dr. Ajai Chari in an in interview with CURE
An image of Dr. Patel in an interview with CURE discussing healthy lifestyles in myeloma
Dr. Munshi in an interview with CURE
Dr. Dikran Kazandjian during an interview with CURE
Looking Ahead Panel
Related Content